Kura Oncology Announces Pricing of Public Offering of Common Stock
November 04, 2015 18:09 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and...
Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
September 30, 2015 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
September 22, 2015 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...